News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,773 Results
Type
Article (40679)
Company Profile (270)
Press Release (676818)
Multimedia
Podcasts (76)
Webinars (17)
Section
Business (204564)
Career Advice (2018)
Deals (35507)
Drug Delivery (105)
Drug Development (81317)
Employer Resources (173)
FDA (16373)
Job Trends (14930)
News (346158)
Policy (32701)
Tag
Academia (2558)
Accelerated approval (23)
Adcomms (24)
Allergies (123)
Alliances (49575)
ALS (157)
Alzheimer's disease (1622)
Antibody-drug conjugate (ADC) (265)
Approvals (16559)
Artificial intelligence (454)
Autoimmune disease (115)
Automation (33)
Bankruptcy (361)
Best Places to Work (11639)
BIOSECURE Act (20)
Biosimilars (173)
Biotechnology (176)
Bladder cancer (147)
Brain cancer (51)
Breast cancer (587)
Cancer (4391)
Cardiovascular disease (358)
Career advice (1700)
Career pathing (34)
CAR-T (261)
CDC (44)
Celiac Disease (1)
Cell therapy (682)
Cervical cancer (34)
Clinical research (69005)
Collaboration (1465)
Company closure (4)
Compensation (1039)
Complete response letters (46)
COVID-19 (2694)
CRISPR (81)
C-suite (685)
Cystic fibrosis (136)
Data (5682)
Decentralized trials (2)
Denatured (25)
Depression (112)
Diabetes (455)
Diagnostics (6601)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (212)
Drug pricing (166)
Drug shortages (28)
Duchenne muscular dystrophy (211)
Earnings (89728)
Editorial (50)
Employer branding (21)
Employer resources (151)
Events (116574)
Executive appointments (937)
FDA (19112)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1320)
Gene editing (180)
Generative AI (38)
Gene therapy (538)
GLP-1 (912)
Government (4624)
Grass and pollen (6)
Guidances (376)
Healthcare (18858)
HIV (48)
Huntington's disease (39)
IgA nephropathy (75)
Immunology and inflammation (229)
Immuno-oncology (36)
Indications (76)
Infectious disease (2934)
Inflammatory bowel disease (178)
Inflation Reduction Act (13)
Influenza (100)
Intellectual property (209)
Interviews (315)
IPO (16621)
IRA (48)
Job creations (3640)
Job search strategy (1427)
Kidney cancer (15)
Labor market (79)
Layoffs (541)
Leadership (28)
Legal (7941)
Liver cancer (88)
Longevity (12)
Lung cancer (606)
Lymphoma (349)
Machine learning (37)
Management (59)
Manufacturing (669)
MASH (152)
Medical device (13686)
Medtech (13723)
Mergers & acquisitions (19847)
Metabolic disorders (1137)
Multiple sclerosis (143)
NASH (16)
Neurodegenerative disease (276)
Neuropsychiatric disorders (69)
Neuroscience (2700)
NextGen: Class of 2025 (6518)
Non-profit (4501)
Now hiring (60)
Obesity (527)
Opinion (247)
Ovarian cancer (149)
Pain (173)
Pancreatic cancer (190)
Parkinson's disease (251)
Partnered (31)
Patents (444)
Patient recruitment (391)
Peanut (54)
People (58519)
Pharmaceutical (63)
Pharmacy benefit managers (26)
Phase I (21503)
Phase II (30375)
Phase III (22649)
Pipeline (3800)
Policy (260)
Postmarket research (2564)
Preclinical (9162)
Press Release (64)
Prostate cancer (214)
Psychedelics (43)
Radiopharmaceuticals (264)
Rare diseases (708)
Real estate (5948)
Recruiting (69)
Regulatory (23931)
Reports (51)
Research institute (2372)
Resumes & cover letters (351)
Rett syndrome (23)
RNA editing (12)
RSV (73)
Schizophrenia (134)
Series A (216)
Series B (165)
Service/supplier (11)
Sickle cell disease (91)
Special edition (20)
Spinal muscular atrophy (153)
Sponsored (40)
Startups (3607)
State (2)
Stomach cancer (16)
Supply chain (97)
Tariffs (80)
The Weekly (49)
Vaccines (944)
Venture capital (74)
Weight loss (340)
Women's health (74)
Worklife (17)
Date
Today (125)
Last 7 days (532)
Last 30 days (2388)
Last 365 days (30273)
2025 (29664)
2024 (35219)
2023 (40076)
2022 (51175)
2021 (55711)
2020 (54083)
2019 (46540)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (734)
Alabama (77)
Alaska (7)
Arizona (288)
Arkansas (13)
Asia (38938)
Australia (6363)
California (10387)
Canada (3086)
China (971)
Colorado (433)
Connecticut (445)
Delaware (307)
Europe (83930)
Florida (1538)
Georgia (330)
Hawaii (2)
Idaho (61)
Illinois (780)
India (54)
Indiana (491)
Iowa (20)
Japan (362)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1305)
Massachusetts (7485)
Michigan (301)
Minnesota (585)
Mississippi (5)
Missouri (120)
Montana (30)
Nebraska (26)
Nevada (112)
New Hampshire (73)
New Jersey (2802)
New Mexico (28)
New York (2766)
North Carolina (1355)
North Dakota (8)
Northern California (4986)
Ohio (305)
Oklahoma (20)
Oregon (38)
Pennsylvania (2129)
Puerto Rico (19)
Rhode Island (45)
South America (1100)
South Carolina (58)
South Dakota (1)
Southern California (4020)
Tennessee (163)
Texas (1600)
United States (37103)
Utah (306)
Vermont (1)
Virginia (238)
Washington D.C. (78)
Washington State (851)
West Virginia (4)
Wisconsin (90)
Wyoming (2)
717,773 Results for "chemocentryx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).
October 20, 2022
·
14 min read
Deals
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
August 4, 2022
·
16 min read
Press Releases
BrYet US, Inc. Expands Patent Portfolio with New U.S. Patent for Targeted Drug Delivery
Near-term applications include combinations with kinase inhibitors (KIs) that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location
November 13, 2025
·
1 min read
Business
ChemoCentryx Announces Changes to its Board of Directors
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
May 31, 2022
·
4 min read
Press Releases
Ophidion, Inc. and Neuronasal, Inc. Announce Strategic Collaborations to Tackle Parkinson’s Disease, Obesity, and Diabetes via Novel CNS Delivery Platform
December 16, 2025
·
3 min read
Business
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.
July 5, 2022
·
4 min read
Business
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET.
August 9, 2022
·
7 min read
Press Releases
Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications
November 26, 2025
·
2 min read
Press Releases
Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference
December 17, 2025
·
1 min read
Press Releases
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
December 17, 2025
·
1 min read
1 of 71,778
Next
